- Home
- NCT vs RAPT Comparison
NCT vs RAPT Comparison
Compare NCT & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCT
- RAPT
- Stock Information
- Founded
- NCT 2011
- RAPT 2015
- Country
- NCT Hong Kong
- RAPT United States
- Employees
- NCT N/A
- RAPT N/A
- Industry
- NCT
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- NCT
- RAPT Health Care
- Exchange
- NCT NYSE
- RAPT Nasdaq
- Market Cap
- NCT 116.0M
- RAPT 117.5M
- IPO Year
- NCT 2025
- RAPT 2019
- Fundamental
- Price
- NCT $3.99
- RAPT $0.89
- Analyst Decision
- NCT
- RAPT Buy
- Analyst Count
- NCT 0
- RAPT 5
- Target Price
- NCT N/A
- RAPT $5.25
- AVG Volume (30 Days)
- NCT 75.1K
- RAPT 1.1M
- Earning Date
- NCT 01-01-0001
- RAPT 05-08-2025
- Dividend Yield
- NCT N/A
- RAPT N/A
- EPS Growth
- NCT N/A
- RAPT N/A
- EPS
- NCT 0.13
- RAPT N/A
- Revenue
- NCT $25,526,936.00
- RAPT N/A
- Revenue This Year
- NCT N/A
- RAPT N/A
- Revenue Next Year
- NCT N/A
- RAPT N/A
- P/E Ratio
- NCT $31.28
- RAPT N/A
- Revenue Growth
- NCT N/A
- RAPT N/A
- 52 Week Low
- NCT $3.05
- RAPT $0.71
- 52 Week High
- NCT $8.76
- RAPT $4.60
- Technical
- Relative Strength Index (RSI)
- NCT N/A
- RAPT 48.13
- Support Level
- NCT N/A
- RAPT $0.81
- Resistance Level
- NCT N/A
- RAPT $1.27
- Average True Range (ATR)
- NCT 0.00
- RAPT 0.14
- MACD
- NCT 0.00
- RAPT 0.01
- Stochastic Oscillator
- NCT 0.00
- RAPT 31.55
About NCT INTERCONT (CAYMAN) LIMITED
Intercont (Cayman) Ltd operates through its subsidiaries. It is principally engaged in the time charter service and vessel management services business.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.